• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Optimark (Gadoversetamide) Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – August 2013

Summary View



Hypersensitivity Reactions
  • Severe hypersensitivity reactions including anaphylaxis have been observed with administration of gadolinium products including Optimark…